GTX Inc. (GTXI) 0.67 $GTXI GTx (GTXI) Shows Strength:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
GTX Inc. (GTXI) 0.67 $GTXI

GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:15AM CDT
GTx, Inc. (GTXI) shares rose almost 18% in the last trading session.
GTXI: 0.67 (+0.07), ANIP: 54.94 (+2.15)

GTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference
BusinessWire - Thu Jun 02, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 9, 2016, at the Jefferies 2016 Global Healthcare Conference in New York City. The GTx presentation will begin at 10:30 am EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 23.
GTXI: 0.67 (+0.07)

GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2016
BusinessWire - Mon May 16, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on May 24, 2016, at the UBS Global Healthcare Conference in New York City. The GTx presentation will begin at 11:30 am EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 7, 2016.
GTXI: 0.67 (+0.07)

GTx posts 1Q profit
Automated Insights - Tue May 10, 6:14AM CDT
MEMPHIS, Tenn. (AP) _ GTx Inc. (GTXI) on Tuesday reported first-quarter net income of $2.1 million, after reporting a loss in the same period a year earlier.
GTXI: 0.67 (+0.07)

GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter ended March 31, 2016, and highlighted recent accomplishments and upcoming milestones. The Company is currently enrolling patients in three clinical trials: two trials evaluating enobosarm as a potential treatment for women with advanced breast cancer and another assessing enobosarm as a potential treatment for stress urinary incontinence in postmenopausal women.
GTXI: 0.67 (+0.07)

GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting
BusinessWire - Mon May 09, 6:00AM CDT
-- Novel SARD compounds being developed initially as a potential treatment for men with castration-resistant prostate cancer --
GTXI: 0.67 (+0.07)

GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016
BusinessWire - Wed Apr 27, 6:00AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2016 financial results press release will be Tuesday, May 10, 2016, prior to the opening of the U.S. stock markets. The Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
GTXI: 0.67 (+0.07)

GTx reports 4Q loss
Automated Insights - Thu Mar 03, 6:17AM CST
MEMPHIS, Tenn. (AP) _ GTx Inc. (GTXI) on Thursday reported a loss of $3.2 million in its fourth quarter.
GTXI: 0.67 (+0.07)

GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
BusinessWire - Thu Mar 03, 6:00AM CST
-- Lead SARD candidates have been selected for additional preclinical studies necessary to initiate first in human clinical trials --
GTXI: 0.67 (+0.07)

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.85 (-0.25), PFE: 34.34 (-0.13), OPHT: 54.75 (+0.59), PFNX: 7.89 (-0.09), OCUL: 5.34 (+0.02), AGN: 229.37 (+0.82), GTXI: 0.67 (+0.07), OHRP: 2.78 (+0.02), AAVL: 4.14 (-0.18), TCON: 5.16 (+0.08), REGN: 355.53 (+3.61), NVS: 80.02 (+0.31)

Myocardial Fibrosis Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/nbcrfp/myocardial) has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Myocardial Fibrosis Overview - Therapeutics Development - Pipeline Products for Myocardial Fibrosis - Overview - Pipeline Products for Myocardial Fibrosis - Comparative Analysis - Myocardial Fibrosis - Therapeutics under Development by Companies - Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes - Myocardial Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myocardial Fibrosis - Products under Development by Companies - Myocardial Fibrosis - Products under Investigation by Universities/Institutes - Myocardial Fibrosis - Companies Involved in Therapeutics Development - AstraZeneca Plc - BioLineRx, Ltd. - Digna Biotech, S.L. - Evotec AG - Galectin Therapeutics, Inc. - GTx, Inc. - MandalMed, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. - Virocan Therapeutics Private Limited For more information visit http://www.researchandmarkets.com/research/nbcrfp/myocardial
GTXI: 0.67 (+0.07), AZN: 28.92 (+0.22), GALT: 1.40 (-0.02)

GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
BusinessWire - Wed Jan 13, 6:00AM CST
-- Objective to determine whether a SARM may increase pelvic floor muscle mass and potentially improve outcomes in women with SUI --
GTXI: 0.67 (+0.07)

Duchenne Muscular Dystrophy - Pipeline Review 2015
M2 - Wed Jan 06, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dsjbc/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Included: - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - BioMarin Pharmaceutical Inc. - Bristol-Myers Squibb Company - Capricor Therapeutics, Inc. - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dong-A Socio Group - Editas Medicine, Inc. - Eli Lilly and Company - EryDel SPA - FibroGen, Inc. - Galapagos NV - Genethon - GTx, Inc. - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - La Jolla Pharmaceutical Company - (20 Others) For more information visit http://www.researchandmarkets.com/research/9d...e_muscular
GTXI: 0.67 (+0.07), CAPR: 4.32 (+0.05), BMRN: 82.57 (+0.39), IDRA: 1.48 (unch), FGEN: 15.76 (+0.26), LLY: 73.29 (+0.22), BMY: 72.25 (-0.06), GLPG: 53.04 (+0.51), XLRN: 33.69 (+0.13)

Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.67 (+0.07), LPTN: 2.34 (-0.11)

Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session
Zacks Equity Research - Zacks Investment Research - Wed Dec 16, 7:20AM CST
GTX Inc. (GTXI) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
GTXI: 0.67 (+0.07), ACHN: 8.47 (+0.07)

World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 8.08 (-0.01), EBS: 30.78 (-0.55), ARWR: 5.73 (+0.05), AMBX: (), PFE: 34.34 (-0.13), ADMP: 2.83 (unch), AMGN: 151.09 (+1.28), LLY: 73.29 (+0.22), BIND: 0.41 (unch), GSK: 42.14 (+0.38), BMY: 72.25 (-0.06), MDVN: 59.43 (+0.54), PGNX: 4.72 (+0.06), GTXI: 0.67 (+0.07), AZN: 28.92 (+0.22), NLNK: 10.67 (+0.02), ABBV: 61.04 (+0.65)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 522

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 442

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 380

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 223

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 460

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 371

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 284

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 259

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Mallinckrodt's Potential Merger with Endo: Key Developments

Updated Category News Views 248

Mallinckrodt's Envisioned Merger with Endo Mallinckrodt plc, a leading global specialty pharmaceutical company, has made striking advancements in its proposed merger with Endo International plc. This significant event in the pharmaceutical industry not only showcases the evolving dynamics between two healthcare giants but also promises to create new opportunities for...

Continue Reading
FFBML Crowned as LendingTree's Top 10 Rated Mortgage Lender

Updated Category News Views 254

Customer Service Takes Center Stage After years of grappling with frustrating lenders, First Federal Bank Mortgage Lenders (FFBML) comes out swinging, earning a shiny new badge of honor—the Q3 2025 Top 10 Rated Lender from LendingTree for customer service in mortgage lending. This isn’t just some arbitrary title; it’s a testament to the grit and determination FFBML...

Continue Reading
Ecobat Successfully Transfers French Lead Operations to Campine

Updated Category News Views 219

Ecobat Finalizes Sale of French Lead Operations DALLAS — Ecobat, recognized as a leader in the battery recycling industry, has finalized the sale of its French lead operations to Campine NV. This transaction follows a strategic pathway outlined by the management to enhance focus on core initiatives within the battery recycling sector. Transaction Details The successful...

Continue Reading
RE/MAX Agents Maintain Dominance in Real Estate Performance

Updated Category News Views 431

RE/MAX Agents Excel in Real Estate Industry Performance In an exciting revelation, data from the 2025 RealTrends Verified rankings has confirmed that RE/MAX agents are once again leading the charge in productivity within the U.S. real estate market. These agents have outperformed their competitors at large brokerages with a striking ratio of 2:1, showcasing remarkable...

Continue Reading
Creo Engine Revolutionizes Blockchain Gaming with New Launches

Updated Category News Views 214

Transforming the Future of Gaming with Creo Engine Creo Engine is stepping up to change the game in the world of blockchain technology. With their innovative approaches, this rising company is bringing exciting solutions to the Web3 gaming community. Recently, they introduced the CreoPlay Bot Mini-app Beta Version, which is a game-changer in how players experience...

Continue Reading